Acquisition of Rigaku MicroMax-007 HF lab x-ray system

描述(由申请人提供)：豪普特曼-伍德沃德医学研究所寻求用另一种旋转阳极，即Rigaku MicroMax-007微焦单元来取代过时的Rigaku RU-200旋转阳极X射线发生器。对于Micromax，我们还需要一个Rigaku土星944+CCD探测器和相关设备，整个系统包括一个完整的X射线数据收集系统。RU-200是在1992年购买的，Rigaku已经宣布将不再支持该机器。不可逆转的故障随时可能发生，更换的需求迫在眉睫。该研究所目前拥有两个图像板探测器，一个是从斯坦福大学借来的MAR 345单元，另一个是我们的主力设备，R轴IV，安装在RU-H3RHB发电机上。MAR部门致力于与斯坦福大学合作的机器人晶体安装项目，很少用于正常的数据收集。有11个NIH资助的项目--加上一系列更初步的项目--在R轴IV上寻找时间，排队的人往往长得令人沮丧。我们认为，迫切需要第二个通用数据收集系统。 与健康相关：蛋白质分子在活体中执行大多数功能，许多药物通过靶向参与疾病过程的蛋白质来发挥作用。所要求的设备将 使我们能够创建各种蛋白质分子的三维图像。这些图像通过让我们根据蛋白质中的互补位置定制药物，极大地加快和改进了药物设计的过程。

DESCRIPTION (provided by applicant): The Hauptman-Woodward Medical Research Institute seeks to replace an obsolete Rigaku RU- 200 rotating anode x-ray generator with another rotating anode, the Rigaku MicroMax-007 microfocus unit. With the Micromax we are also requesting a Rigaku Saturn 944+ CCD detector and related equipment, the whole comprising a complete X-ray data collection system. The RU-200 was purchased in 1992, and Rigaku has announced that the machine will no longer be supported. Irreversible failure could happen at any time, and the need for replacement is urgent. The Institute currently houses two image plate detectors, one a MAR 345 unit on loan from Stanford and the other our workhorse, an R AXIS IV sited on a RU-H3RHB generator. The MAR unit is dedicated to a collaborative project with Stanford on robotic crystal mounting, and is rarely available for normal data collection. There are 11 NIH-funded projects - plus a slew of more preliminary ones - seeking time on the R AXIS IV, and the queue is often discouragingly long. We feel that the need for a second general purpose data collection system is compelling. HEALTH RELEVANCE: Protein molecules carry out most of the functions in living organisms, and many drugs work by targeting proteins involved in a disease process. The requested equipment will allow us to create three-dimensional images of various protein molecules. These images greatly expedite and refine the process of designing drugs by letting us tailor the drug to its complementary site in the protein.